MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Cardiovascular
  • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • Videos
    • Whitepapers
  • DeviceTalks
You are here: Home / News Well / CardioKinetix’s cath-based Parachute may “revolutionize” treatment

CardioKinetix’s cath-based Parachute may “revolutionize” treatment

May 18, 2012 By MassDevice staff Leave a Comment

CardioKinetix Parachute

CardioKinetix made strides in research for its novel Parachute catheter-based left ventricle implant, which proved promising after 2 years in study results unveiled at this year’s EuroPCR conference in Paris.

The Parachute is inserted into the heart via a catheter threaded through the femoral artery. Once inside the heart, the device springs open and attaches to the walls of the heart to provide support for patients whose left ventricle was left enlarged after a heart attack.

The device aims to partition the damaged muscle from the healthy, functional parts of the heart in order to decrease the burden on the ventricle.

The pair of 1st-in-human studies showed that patients with the Parachute implant after 2 years generally improved their heart failure score by an entire class, as graded on the New York Heart Assn. rating system.

"It is difficult to contain our enthusiasm because the procedure is relatively simple and the outcomes are surprisingly remarkable for such a high-risk population," investigator Dr. Marco Costa said in prepared remarks. "If these results are confirmed in the upcoming large randomized trial, the Parachute implant will revolutionize the treatment of patients with ischemic dilated cardiomyopathy."

The study involved 31 patients treated in the U.S. and Europe over 2 years, during which time the rate of cardiac death was 6.5%, and all-cause mortality was 32.3%. Those figures "compare favorably" with current medical therapy, according to a press release.

The data supports the design for a larger, randomized pivotal trial that will in turn support a bid for FDA approval.

"We are extremely pleased with the 2-year clinical results from the Parachute implant," investigator Dr. William Abraham said in prepared remarks. "This innovative device has the potential to bring together two cardiology disciplines – heart failure and interventional cardiology – to address a significant unmet need in heart failure.

Filed Under: News Well Tagged With: CardioKinetix Inc., Clinical Trials, EuroPCR

In case you missed it

  • Medtronic faces patent lawsuit over CoreValve tech
  • Orpyx launches sensory insoles with patient monitoring
  • Ortho devicemakers Hensler and Tobra face off in patent lawsuit
  • House bill asks CMS to cover breakthrough devices for Medicare patients
  • Empirical Spine completes enrollment in LimiFlex pivotal trial
  • MolecuLight wins FDA clearance for handheld imaging device
  • Medical device tax will cost 20,000 jobs, report says
  • W.L. Gore officials think they can spur insulin delivery system innovation
  • EPA moves closer to stricter regulations on medtech ethylene oxide sterilization
  • 3DBio Therapeutics wins FDA rare pediatric disease designation for outer ear reconstruction
  • CryoLife wins CE Mark for E-nya thoracic stent graft
  • Edwards projects $5 billion in sales for 2020
  • SPR Therapeutics announces 1000th placement of nerve stimulation device
  • The best places to work for medtech sales reps
  • DePuy Synthes issues urgent field safety notice for USS II Polyaxial 3D heads
  • Haemonetics (HAE) launches SafeTrace Tx in North America
  • Vicarious Surgical wins FDA breakthrough designation for surgical robot

RSS From Medical Design & Outsourcing

Leave a Reply Cancel reply

You must be logged in to post a comment.

Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Popular Posts

  • Report: SEC probes GE Healthcare, Philips, Siemens in Chinese bribery scheme
  • Edwards Lifesciences warns against below-market mini-tender offer Edwards Lifesciences
  • J&J’s Ethicon files ITC complaint against Intuitive Surgical Intuitive Surgical's EndoWrist instruments
  • Auris Health loses motion to move Intuitive Surgical patent suit from Del. to Cali. Johnson & Johnson's Auris, Intuitive Surgical
  • Enable Injections inks deal with Sanofi for drug delivery platform enfuse-enable-injections
Tweets by @MassDevice
MDO ad

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us
Add us on FacebookMassDevice Network
Follow us on Twitter@MassDevice
Connect with us on LinkedInLinkedIn
Follow us on YouTube YouTube

Copyright © 2019 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS